TY - JOUR AU - Coit, D. G. AU - Thompson, J. A. AU - Algazi, A. AU - Andtbacka, R. AU - Bichakjian, C. K. AU - Carson, W. E. PY - 2016 DA - 2016// TI - Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology JO - J Natl Compr Cancer Netw. VL - 14 UR - https://doi.org/10.6004/jnccn.2016.0051 DO - 10.6004/jnccn.2016.0051 ID - Coit2016 ER - TY - JOUR AU - Wang, J. AU - Chmielowski, B. AU - Pellissier, J. AU - Xu, R. AU - Stevinson, K. AU - Liu, F. X. PY - 2017 DA - 2017// TI - Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naive patients with advanced melanoma in the United States JO - J Manag Care Spec Pharm. VL - 23 ID - Wang2017 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Schadendorf, D. AU - Hodi, F. S. AU - Robert, C. AU - Weber, J. S. AU - Margolin, K. AU - Hamid, O. PY - 2015 DA - 2015// TI - Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2736 DO - 10.1200/JCO.2014.56.2736 ID - Schadendorf2015 ER - TY - JOUR AU - Balch, C. M. AU - Buzaid, A. C. AU - Soong, S. J. AU - Atkins, M. B. AU - Cascinelli, N. AU - Coit, D. G. PY - 2001 DA - 2001// TI - Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.16.3635 DO - 10.1200/JCO.2001.19.16.3635 ID - Balch2001 ER - TY - STD TI - Hong Kong Life Tables 2011–2066. 2017 ed: Census & Statistics Department, The Government of the HKSAR. ID - ref6 ER - TY - STD TI - Technical report: updated systematic literature review and network meta-analysis of pembrolizumab for the treatment of advanced melanoma. ID - ref7 ER - TY - JOUR AU - Schachter, J. AU - Ribas, A. AU - Long, G. V. AU - Arance, A. AU - Grob, J. -. J. AU - Mortier, L. PY - 2017 DA - 2017// TI - Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) JO - Lancet VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)31601-X DO - 10.1016/S0140-6736(17)31601-X ID - Schachter2017 ER - TY - JOUR AU - Hauschild, A. AU - Grob, J. J. AU - Demidov, L. V. AU - Jouary, T. AU - Gutzmer, R. AU - Millward, M. PY - 2012 DA - 2012// TI - Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial JO - Lancet VL - 380 UR - https://doi.org/10.1016/S0140-6736(12)60868-X DO - 10.1016/S0140-6736(12)60868-X ID - Hauschild2012 ER - TY - STD TI - Cytotoxics Drug Price List—Prince of Wales Hospital, Hospital Authority. 2018. ID - ref10 ER - TY - JOUR AU - McArthur, G. A. AU - Mohr, P. AU - Ascierto, P. A. AU - Arance, A. AU - Hernaez, A. B. AU - Kaskel, P. PY - 2017 DA - 2017// TI - Health care resource utilization and associated costs among metastatic cutaneous melanoma patients treated with Ipilimumab (INTUITION Study) JO - Oncologist VL - 22 UR - https://doi.org/10.1634/theoncologist.2016-0272 DO - 10.1634/theoncologist.2016-0272 ID - McArthur2017 ER - TY - JOUR AU - Wong, I. O. AU - Kuntz, K. M. AU - Cowling, B. J. AU - Lam, C. L. AU - Leung, G. M. PY - 2007 DA - 2007// TI - Cost effectiveness of mammography screening for Chinese women JO - Cancer VL - 110 UR - https://doi.org/10.1002/cncr.22848 DO - 10.1002/cncr.22848 ID - Wong2007 ER - TY - STD TI - National Institute for Health and Care Excellence (NICE). Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma. Technology appraisal guidance [TA268]. Manufacturer submission. 2012. https://www.nice.org.uk/guidance/ta268/documents/melanoma-stage-iii-or-iv-ipilimumab-manufacturers-submission-bristol-myerssquibb2. Accessed cited 8 Jan 2020. UR - https://www.nice.org.uk/guidance/ta268/documents/melanoma-stage-iii-or-iv-ipilimumab-manufacturers-submission-bristol-myerssquibb2 ID - ref13 ER - TY - STD TI - Government of Hong Kong: Hospital Authority Ordinance. Chapter 113. https://www.elegislation.gov.hk/hk/cap113. Accessed 24 Aug 2018. UR - https://www.elegislation.gov.hk/hk/cap113 ID - ref14 ER - TY - JOUR AU - Eisen, T. AU - Trefzer, U. AU - Hamilton, A. AU - Hersey, P. AU - Millward, M. AU - Knight, R. D. PY - 2010 DA - 2010// TI - Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma JO - Cancer VL - 116 ID - Eisen2010 ER - TY - JOUR AU - Hofmann, M. A. AU - Hauschild, A. AU - Mohr, P. AU - Garbe, C. AU - Weichenthal, M. AU - Trefzer, U. PY - 2011 DA - 2011// TI - Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial JO - Melanoma Res VL - 21 UR - https://doi.org/10.1097/CMR.0b013e3283485ff0 DO - 10.1097/CMR.0b013e3283485ff0 ID - Hofmann2011 ER - TY - JOUR AU - Agarwala, S. S. PY - 2009 DA - 2009// TI - Current systemic therapy for metastatic melanoma JO - Expert Rev Anticancer Ther VL - 9 UR - https://doi.org/10.1586/era.09.25 DO - 10.1586/era.09.25 ID - Agarwala2009 ER - TY - JOUR AU - Chen, S. C. AU - Toy, M. AU - Yeh, J. M. AU - Wang, J. D. AU - Resch, S. PY - 2013 DA - 2013// TI - Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment JO - Pediatrics VL - 131 UR - https://doi.org/10.1542/peds.2012-1262 DO - 10.1542/peds.2012-1262 ID - Chen2013 ER - TY - JOUR AU - Hodi, F. S. AU - Hwu, W. J. AU - Kefford, R. AU - Weber, J. S. AU - Daud, A. AU - Hamid, O. PY - 2016 DA - 2016// TI - Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.0391 DO - 10.1200/JCO.2015.64.0391 ID - Hodi2016 ER -